Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine : results from a population-based prospective cohort in Catalonia, Spain, 2020
Vivanco-Hidalgo, Rosa Maria (Hospital del Mar (Barcelona, Catalunya))
Molina Romero, Israel (Hospital Universitari Vall d'Hebron)
Martinez, Elisenda (Agència de Qualitat i Avaluació Sanitàries de Catalunya)
Roman-Viñas, Ramón (Agència de Qualitat i Avaluació Sanitàries de Catalunya)
Sánchez-Montalvá, Adrián (Hospital Universitari Vall d'Hebron)
Fibla, Joan (Institut de Recerca Biomèdica de Lleida)
Pontes García, Caridad (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Velasco Muñoz, César (Agència de Qualitat i Avaluació Sanitàries de Catalunya)

Data:	2021
Resum:	Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine. We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes. We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1. 4%) COVID-19 cases in the exposed cohort and 183 (1. 4%) among controls. The incidence rate was very similar between the two groups (12. 05 vs 11. 35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1. 08; 95% confidence interval (CI): 0. 83-1. 44; p = 0. 50). Forty cases (0. 6%) were admitted to hospital in the exposed cohort and 50 (0. 4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0. 91-2. 34; p = 0. 10). Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	SARS-CoV-2 ; COVID-19 ; Coronavirus ; Chloroquine ; Hydroxychloroquine ; Pre-exposure prophylaxis
Publicat a:	Eurosurveillance, Vol. 26 (march 2021) , ISSN 1560-7917

DOI: 10.2807/1560-7917.ES.2021.26.9.2001202
PMID: 33663646

9 p, 235.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats